insights_auto
Hvorfor har OKYO gått ned? 2,73%?
Gå mer i dybdenchevron_right
OKYO:NASDAQ
OKYO Pharma Ltd
1,39 USD
arrow_downward
−2,73%(−0,039) 1 D
8. okt., 16:00:00 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for OKYO …
Åpne
1,43 USD
Høy
1,46 USD
Lav
1,35 USD
Markedsverdi
72,95 mill.
Snittvolum
73,65k
Volum
2,00
52 u høy
3,20 USD
52 u lav
1,26 USD
EPS
−0,32 USD
Beta
−0,03
Utestående aksjer
52,48 mill.
Antall ansatte
5
Åpne
1,43 USD
Høy
1,46 USD
Lav
1,35 USD
Markedsverdi
72,95 mill.
Snittvolum
73,65k
Volum
2,00
52 u høy
3,20 USD
52 u lav
1,26 USD
EPS
−0,32 USD
Beta
−0,03
Utestående aksjer
52,48 mill.
Antall ansatte
5
Nyhetssaker
Fra nettkilder og nyhetspartnere
Investing.com
·
for 2 døgn siden
H.C. Wainwright reiterates Okyo Pharma stock rating on trial enrollment
TipRanks
·
for 3 døgn siden
OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
Yahoo Finance
·
for 3 døgn siden
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
Stock Titan
·
for 3 døgn siden
A painful eye-nerve condition has no FDA-approved treatment. A trial has enrolled its first patients.
Om OKYO Pharma Ltd